gefitinib has been researched along with 1,2,3,4,5,6-hexabromocyclohexane in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (1,2,3,4,5,6-hexabromocyclohexane) | Trials (1,2,3,4,5,6-hexabromocyclohexane) | Recent Studies (post-2010) (1,2,3,4,5,6-hexabromocyclohexane) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 6 | 0 | 3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, X; Ho, WT; Ishii, T; Li, Q; Li, Z; Xing, S; Xu, M; Zhao, ZJ | 1 |
1 other study(ies) available for gefitinib and 1,2,3,4,5,6-hexabromocyclohexane
| Article | Year |
|---|---|
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.
Topics: Amino Acid Substitution; Animals; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Enzyme Activation; Erlotinib Hydrochloride; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Janus Kinase 2; Jurkat Cells; Mice; Phenylalanine; Polycythemia Vera; Protein Kinase Inhibitors; Quinazolines; Valine | 2007 |